This research aims to evaluate the effectiveness of various treatment options for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Conducted a randomized trial assessing treatment approaches for MOGAD
Monitored clinical outcomes over a defined follow-up period
Analyzed data from multiple centers for comprehensive results.
Identified significant improvements in clinical outcomes for patients receiving specific therapies
Notable response rates were observed among treated groups, indicating effective management strategies
Details of effect sizes and statistical significance provided for major therapeutic interventions.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is now recognized as a distinct inflammatory demyelinating disorder of the central nervous system (CNS), separate fr...